



Wednesday, December 10, 2025

Presentations and Posters at the San Antonio Breast Cancer Symposium

All times listed are Central Standard Time. Times and locations subject to change by SABCS.

Presentation	Speaker	Time/Location
Trade: 6-month abemaciclib tolerability after initial dose escalation in early HR+/HER2- breast cancer Poster Spotlight 1: Addressing Breast Cancer Disparities and Treatment Related Toxicities	Ilana Schlam, MD, MPH	7 – 8:30 a.m. Hemisfair 3
Convergent genomic evolution from early to lethal HR+/HER2- metastatic breast cancer Poster Spotlight 2: Molecular Evolution in Early and Late Stage Tumors	Nolan Priedigkeit, MD, PhD	7 – 8:30 a.m. 301 ABC
Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network Poster Spotlight 3: Emerging Paradigms of CDK Inhibitor and Antibody Drug Conjugate Resistance in Metastatic Breast Cancer	Ana Garrido-Castro, MD	7 – 8:30 a.m. 302 ABC
Clinical Case Discussion	Harold Burstein, MD, PhD Moderator	Noon – 12:50 p.m. Stars at Night 1-2
Educational Session 6: ADCs in the Clinic	Adrienne G. Waks, MD Moderator	2:30 – 4:15 p.m. Stars at Night 1-2

Continued >





Wednesday, December 10, 2025

Poster Session 1

12:30 – 2 p.m. | Exhibit Hall

Poster	Presenter
PS1-01-12: Preventing Chemotherapy-Induced Peripheral Neuropathy with Acupuncture: Preliminary Results of a Pooled Analysis of Three Parallel Randomized Trials	Weidong Lu, MB, MPH, PhD, LicAc
PS1-03-09: Symptoms, survivorship concerns, and alleviation methods among young adults newly diagnosed with early-stage breast cancer	Julia Stal, PhD
PS1-02-01: Knowledge, risk perception, and decision making in patients with a history of ductal carcinoma in situ (DCIS) or atypical breast lesions: a secondary analysis from the PORTAL Study	Carmine Valenza, MD, MPH
PS1-02-28: Quality of life of women after breast surgery: report from Mirebalais University Hospital in Haiti	Temidayo Fadelu, MD, MPH
PS1-04-15: A focused evaluation of young adults living with metastatic breast cancer: Patient-reported strategies to alleviate disease symptoms, treatment-related side effects, and survivorship concerns	Kate Dibble, PhD
PS1-10-18: Genomic analysis of ER+/HER2- metastatic invasive lobular carcinoma (ILC) and clinical outcomes comparison with metastatic invasive carcinoma of no special type (NST)	Kristina Fanucci, MD, MHS
PS1-10-25: Pharmacodynamic effects of the first-in-class CDK4-selective inhibitor atimociclib (PF-07220060) in combination with endocrine therapy in tumors of patients with HR+/HER2- metastatic breast cancer	Antonio Giordano, MD, PhD
PS1-09-02: Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): Results from Cohort C of the DATO-BASE phase 2 trial	Paolo Tarantino, MD, PhD

Continued >





Wednesday, December 10, 2025

Poster Session 2

5 – 6:30 p.m. | Exhibit Hall

Poster	Presenter
PS2-02-07: Impact of BRCA homozygous copy loss on clinical outcomes of patients (pts) with metastatic breast cancer (MBC) treated with PARP inhibitors (PARPi)	Adela Rodriguez-Hernandez, MD
PS2-07-10: A Single Cell Peripheral Blood Immune Cell Atlas of Breast Cancer Disease States by Race reveals Differences in Peripheral Blood Immune Cell Composition and Functional Pathways	Fangyuan Chen, MD
PS2-07-16: Clinicogenomic characterization and ctDNA detection of ESR1 fusion positive metastatic breast cancer	Katheryn Santos
PS2-08-10: Peripheral immune profiling during neoadjuvant HER2-targeted therapy in HER2-positive (HER2+) early breast cancer (EBC): Mass cytometry (CyTOF) analysis from the MARGOT trial	Elia Segui, MD
PS2-08-15: Characterization of Functional Estrogen Receptor (ER) Dependence via Comprehensive Epigenomic Liquid Biopsy Stratifies Endocrine Therapy (ET) Responders with Metastatic Breast Cancer (MBC)	Stefania Morganti, MD
PS2-11-27: Whole-genome doubling promotes immune evasion in TNBC by epigenetically silencing antigen presentation pathways through PRC2 activity	Pierre Foidart, MD, PhD
PS2-13-13: Mortality in HER2-positive male breast cancer between 2010 and 2022: A population-based study	Jose P. Leone, MD